| Name | Title | Contact Details |
|---|---|---|
Madonna Moreno |
Director, Human Resources | Profile |
Medical Communication Systems is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Civitas Senior Living is a team of senior living experts that provide all facets of senior living operations. This expertise includes extensive experience in Assisted Living, Memory Care, and Independent Living. Through third-party management contracts, Civitas provides expert management services for operational start-ups, turn-around operations, and on-going operations. Civitas Senior Living works closely with developers to optimize operations through developing partnerships that align interests. When contracting with Civitas Senior Living, you are partnering with an experienced operator that is also an owner. This ownership experience provides a proven track record of operating properties with excellent financial returns and high occupancy rates while focusing on customer satisfaction.
Hyphen is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lumeris is a value-based care managed services operator for health systems and providers seeking extraordinary clinical and financial outcomes. Lumeris aligns providers and payers across populations with technologies, processes, behaviors and information to achieve high-quality, cost-effective care with satisfied consumers — and engaged physicians. Lumeris with Essence Healthcare, its inaugural client with more than 60,000 Medicare members in Missouri and Illinois, has averaged a CMS rating of 4.5 Stars for the last ten years and produced the highest consumer and physician satisfaction scores in the industry along with significantly better clinical outcomes and lower costs.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.